NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.
NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.
Recruiting · NCT06781281 · Registry updated 2025-06-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer. | Breast Cancer Invasive | Recruiting | Not stated | 2025-06-23 | NCT06781281 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Henan Cancer Hospital | 147 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Henan Cancer Hospital | Zhengzhou | China | 60 |